XML 47 R37.htm IDEA: XBRL DOCUMENT
v3.19.1

Revenues (Details) - USD ($) $ in Millions | 3 Months Ended
--- | ---
Mar. 31, 2019 | Mar. 31, 2018
Disaggregation of Revenue [Line Items] |  |
Revenues | $ 5,281 | $ 5,088
Revenues | 5,281 | 5,088
U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 3,818 | 3,547
Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 938 | 1,057
Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 525 | 484
Atripla |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 171 | 314
Atripla | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 133 | 228
Atripla | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 16 | 51
Atripla | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 22 | 35
Biktarvy |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 793 | 35
Biktarvy | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 739 | 35
Biktarvy | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 48 | 0
Biktarvy | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 6 | 0
Complera/Eviplera |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 115 | 190
Complera/Eviplera | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 44 | 67
Complera/Eviplera | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 62 | 109
Complera/Eviplera | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 9 | 14
Descovy |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 342 | 361
Descovy | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 233 | 274
Descovy | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 68 | 75
Descovy | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 41 | 12
Genvoya |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 1,015 | 1,082
Genvoya | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 728 | 853
Genvoya | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 193 | 186
Genvoya | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 94 | 43
Odefsey |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 397 | 342
Odefsey | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 282 | 279
Odefsey | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 106 | 58
Odefsey | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 9 | 5
Stribild |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 96 | 174
Stribild | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 67 | 133
Stribild | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 18 | 29
Stribild | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 11 | 12
Truvada |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 606 | 652
Truvada | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 551 | 507
Truvada | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 33 | 97
Truvada | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 22 | 48
Other HIV |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 17 | 13
Other HIV | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 11 | 9
Other HIV | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 1 | 1
Other HIV | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 5 | 3
Revenue share - Symtuza |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 66 | 7
Revenue share - Symtuza | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 42 | 0
Revenue share - Symtuza | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 24 | 7
Revenue share - Symtuza | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 0 | 0
AmBisome |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 93 | 107
AmBisome | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 8 | 17
AmBisome | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 57 | 56
AmBisome | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 28 | 34
Ledipasvir/Sofosbuvir |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 225 | 348
Ledipasvir/Sofosbuvir | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 117 | 234
Ledipasvir/Sofosbuvir | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 27 | 56
Ledipasvir/Sofosbuvir | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 81 | 58
Letairis |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 197 | 204
Letairis | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 197 | 204
Letairis | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 0 | 0
Letairis | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 0 | 0
Ranexa |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 155 | 195
Ranexa | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 155 | 195
Ranexa | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 0 | 0
Ranexa | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 0 | 0
Sofosbuvir/Velpatasvir |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 491 | 536
Sofosbuvir/Velpatasvir | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 230 | 269
Sofosbuvir/Velpatasvir | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 154 | 198
Sofosbuvir/Velpatasvir | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 107 | 69
Vemlidy |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 101 | 58
Vemlidy | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 65 | 47
Vemlidy | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 4 | 3
Vemlidy | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 32 | 8
Viread |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 72 | 97
Viread | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 12 | 7
Viread | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 14 | 30
Viread | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 46 | 60
Vosevi |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 63 | 107
Vosevi | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 45 | 86
Vosevi | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 16 | 16
Vosevi | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 2 | 5
Yescarta |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 96 | 40
Yescarta | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 90 | 40
Yescarta | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 6 | 0
Yescarta | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 0 | 0
Zydelig |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 27 | 33
Zydelig | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 11 | 14
Zydelig | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 15 | 18
Zydelig | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 1 | 1
Other(3) |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 62 | 106
Other(3) | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 36 | 29
Other(3) | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 20 | 15
Other(3) | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 6 | 62
Product sales |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 5,200 | 5,001
Product sales | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 3,796 | 3,527
Product sales | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 882 | 1,005
Product sales | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 522 | 469
Royalty, contract and other revenues |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 81 | 87
Revenues | 81 | 87
Royalty, contract and other revenues | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 22 | 20
Royalty, contract and other revenues | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 56 | 52
Royalty, contract and other revenues | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | $ 3 | $ 15

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=gild_OtherInternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsStribildMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsVemlidyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsVireadMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductsVoseviMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |